The Radiochemistry and Instrumentation Support Laboratory (RISL) is one of the core facilities and shared resources of The Ohio State University (OSU) Comprehensive Cancer Center (CCC). The purposes of the RISL are fivefold: (1) to provide custom synthesis of radiochemicals not available commercially to investigators of the OSUCCC, (2) to perform purification of custom preparations of chemically-labile radiochemicals, (3) to aid in the purchase of radiochemicals, advice on the use of radiochemical products and equipment, and provide radiation safety expertise to the CCC, (4) to provide organic chemical support services [synthesis, isolation, structure determination, chemistry expertise] for CCC investigators, and (5) to maintain chemical instrumentation for the isolation and structure determination of carcinogens, drugs, metabolites, and biochemical compounds and general equipment for biochemical/biological research. Robert W. Brueggemeier, Ph.D. is director of the Radiochemistry and Instrumentation Support Laboratory and is involved with projects both as a shared resource person and as a principal investigator within he OSUCCC. Michael V. Darby, Ph.D. serves as the full-time synthetic radiochemist in the Radiochemistry Laboratory. Drs. Brueggemeier and Darby co-direct a graduate research assistant and work closely with cost doctoral research and technicians on the various projects utilizing radiochemistry and chemistry services. Several research and service activities were expanded or introduced since July 1995. These additional services include development of methods of determination of 8-hydroxydeoxyguanosine levels by HPLC- electrochemical detection, expansion of iodination procedures using a variety of reagents, acquisition and installation of new instrumentation and relocation of instruments into laboratory facilities where the instruments are more effectively utilized. The RISL will continue to be an effective radiochemistry and instrumentation support facility for cancer research, diagnosis, or treatment that is encompassed in the OSU Comprehensive Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-27
Application #
6563730
Study Section
Project Start
2001-12-01
Project End
2002-11-30
Budget Start
Budget End
Support Year
27
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Baldassari, Federica; Zerbinati, Carlotta; Galasso, Marco et al. (2018) Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors. Front Genet 9:174
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643
Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723
Ngankeu, Apollinaire; Ranganathan, Parvathi; Havelange, Violaine et al. (2018) Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9:4354-4365
Lopez, Cecilia M; Yu, Peter Y; Zhang, Xiaoli et al. (2018) MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines. PLoS One 13:e0190086
Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572
Lampis, Andrea; Carotenuto, Pietro; Vlachogiannis, Georgios et al. (2018) MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology 154:1066-1079.e5
Le Gallo, Matthieu; Rudd, Meghan L; Urick, Mary Ellen et al. (2018) The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. Cancer 124:65-73
Jones, Jeffrey A; Mato, Anthony R; Wierda, William G et al. (2018) Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 19:65-75
Madan, Esha; Parker, Taylor M; Bauer, Matthias R et al. (2018) The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53. J Biol Chem 293:4262-4276

Showing the most recent 10 out of 2602 publications